MY199399A - Novel polysaccharide-protein conjugates and process to obtain thereof - Google Patents

Novel polysaccharide-protein conjugates and process to obtain thereof

Info

Publication number
MY199399A
MY199399A MYPI2018703258A MYPI2018703258A MY199399A MY 199399 A MY199399 A MY 199399A MY PI2018703258 A MYPI2018703258 A MY PI2018703258A MY PI2018703258 A MYPI2018703258 A MY PI2018703258A MY 199399 A MY199399 A MY 199399A
Authority
MY
Malaysia
Prior art keywords
protein conjugates
relates
present
novel polysaccharide
polysaccharide
Prior art date
Application number
MYPI2018703258A
Inventor
Rakesh Rana
Juned Dalal
Manoj Kumar Chhikara
Davinder Gill
Original Assignee
Msd Wellcome Trust Hilleman Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Wellcome Trust Hilleman Laboratories Pvt Ltd filed Critical Msd Wellcome Trust Hilleman Laboratories Pvt Ltd
Publication of MY199399A publication Critical patent/MY199399A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to novel polysaccharide-protein conjugates and process to obtain the same. More particularly, the present invention relates to polysaccharide protein conjugates produced using carbamate chemistry capable of being used in production of monovalent vaccine or multivalent combination vaccines as well as a diagnostic tool. More specifically the present invention relates to Neisseria meningitidis serogroup X, A, C, Y and W135 polysaccharidecarrier protein conjugate using carbamate chemistry and the process to obtain the same.
MYPI2018703258A 2016-03-15 2017-03-10 Novel polysaccharide-protein conjugates and process to obtain thereof MY199399A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201611008901 2016-03-15
PCT/IB2017/051408 WO2017158480A1 (en) 2016-03-15 2017-03-10 Novel polysaccharide-protein conjugates and process to obtain thereof

Publications (1)

Publication Number Publication Date
MY199399A true MY199399A (en) 2023-10-25

Family

ID=59851687

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018703258A MY199399A (en) 2016-03-15 2017-03-10 Novel polysaccharide-protein conjugates and process to obtain thereof

Country Status (10)

Country Link
JP (1) JP2019508468A (en)
KR (1) KR102428253B1 (en)
CN (1) CN108883192A (en)
AU (1) AU2017234319B2 (en)
BR (1) BR112018068523A2 (en)
MX (1) MX2018010920A (en)
MY (1) MY199399A (en)
RU (1) RU2758090C2 (en)
WO (1) WO2017158480A1 (en)
ZA (1) ZA201806043B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Vaccines US Inc. Neisseria meningitidis vaccine
WO2019003238A1 (en) * 2017-06-27 2019-01-03 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel multivalent polysaccharide – protein conjugate vaccine composition and formulation thereof
CN110652585B (en) * 2018-10-26 2023-05-26 武汉博沃生物科技有限公司 Polysaccharide-protein conjugate immune preparation and application thereof
CN110302375A (en) * 2019-06-27 2019-10-08 康希诺生物股份公司 A kind of glycoconjugate and use thereof
RU2770877C1 (en) * 2021-04-08 2022-04-22 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Method of producing antigenic conjugated substance of haemophilic type b microbe for creating vaccine preparations
CN114965784B (en) * 2022-06-01 2023-10-27 艾美探索者生命科学研发有限公司 Method for measuring polysaccharide activation degree
CN116087363B (en) * 2023-02-15 2025-03-14 北京生物制品研究所有限责任公司 A method for detecting the content of carboxymethyl dextran in adsorption vaccines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
RU2233172C2 (en) * 1997-07-17 2004-07-27 Бакстэ Хелскеа С.А. Haemophilus influenzae immunogenic conjugate polysaccharide - porin of meningococcus group b (variants), method for its preparing, pharmaceutical composition and method for immune response induction in animal with regards to haemophilus influenzae
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
US9486515B2 (en) * 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
CN1709505B (en) * 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 Multivalent Bacterial Capsular Polysaccharide-Protein Conjugate Vaccine
TWI505834B (en) * 2009-06-22 2015-11-01 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
HUE040914T4 (en) * 2012-01-30 2019-05-28 Serum Institute Of India Pvt Ltd Immunogenic composition
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines

Also Published As

Publication number Publication date
RU2018135066A3 (en) 2020-11-10
WO2017158480A1 (en) 2017-09-21
CN108883192A (en) 2018-11-23
BR112018068523A2 (en) 2019-01-22
KR102428253B1 (en) 2022-08-02
ZA201806043B (en) 2019-05-29
AU2017234319B2 (en) 2021-11-04
KR20180121564A (en) 2018-11-07
MX2018010920A (en) 2019-03-06
RU2758090C2 (en) 2021-10-26
RU2018135066A (en) 2020-04-06
AU2017234319A1 (en) 2018-09-27
JP2019508468A (en) 2019-03-28

Similar Documents

Publication Publication Date Title
MY199399A (en) Novel polysaccharide-protein conjugates and process to obtain thereof
PH12021550318A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2020002558A (en) Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein.
AR118199A2 (en) IMMUNOGENIC COMPOSITIONS OF NON-LIPID NON-PIRUVILATED VARIANTS OF ORF2086 ANTIGENS FROM NEISSERIA MENINGITIDIS, POLIPEPTIDES, NUCLEOTIDE SEQUENCES AND PLASMIDS
BR112012007876A2 (en) "ion exchange membranes"
PH12018501517A1 (en) Neisseria meningitidis compositions and methods thereof
PH12018500037A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
IN2014DN09791A (en)
TN2017000126A1 (en) An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof
SA519401227B1 (en) Neisseria Meningitidis Vaccine
MX2021013109A (en) Process for preparing an attenuated tetravalent dengue vaccine.
MX2020002084A (en) Peptide conjugates, conjugation process, and uses thereof.
IL284349A (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine
WO2018042017A3 (en) Vaccines for neisseria gonorrhoeae
MY192792A (en) A composition of multivalent pneumococcal capsular polysaccharide-carrier protein conjugates and use thereof
MY194920A (en) Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof
BR112012007877A2 (en) means and methods for producing artificial capsular polysaccharides of neisseria meningitidis
WO2015158898A3 (en) Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
BR112018001425A2 (en) new serogroup y oligomers of neisseria meningitidis and their synthesis processes
IN2014MU00349A (en)